Fragments of DNA that float freely in the bloodstream after being released by dying or damaged cells, like puzzle pieces carried downstream that hint at what’s happening upstream. Investors care because measuring these fragments enables non‑invasive tests — for example to detect cancer, monitor treatment response, check pregnancy health, or spot organ rejection — so advances, approvals, or reimbursement changes can quickly affect companies that develop the tests and related technologies.
precision medicinemedical
Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.
sequencing facilitytechnical
A sequencing facility is a specialized lab that reads the order of DNA or RNA letters using high-capacity machines and turns biological material into digital data, like a printing press that converts text into many copies. Investors care because these centers are capital-intensive service hubs that enable drug discovery, diagnostics and research partnerships; their capacity, data quality and regulatory compliance can directly affect revenue, timelines and competitive advantage.
companion diagnosticmedical
A companion diagnostic is a medical test designed to identify which patients are likely to benefit from a specific drug or medical treatment, much like a key that shows whether a particular lock will open. For investors, these tests matter because they can increase a drug’s chances of approval and market uptake, create a separate revenue stream, and reduce commercial risk by matching treatments to the patients most likely to respond.
molecular residual diseasemedical
Molecular residual disease is the tiny amount of cancer that can remain in the body after treatment and is detectable only by sensitive tests that find cancer DNA or other molecular traces. It matters to investors because these measurements can predict relapse, guide whether additional therapy is needed, and shape the market for diagnostics and drugs—much like finding embers after a fire helps decide if more firefighting is required.
clinical trialsmedical
Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
Company to open second facility and new lab space to accommodate rapid growth
AUSTIN, Texas--(BUSINESS WIRE)--
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milestone in the company’s continued growth and mission to improve outcomes for patients with cancer and other serious diseases.
At its North Austin headquarters campus, Natera will unveil two major expansion projects: a dedicated sequencing facility, significantly increasing capacity; and an additional space in a second building within the same complex, designed to support continued business growth and operational scale.
Natera’s facility is expected to have the largest sequencing capacity in the world. This new space will help enable the company to meet the increasing demand for its testing solutions, particularly in oncology where year-over-year volumes increased by more than 54% in the first quarter of 2026. Natera's SignateraTM test has become a foundational tool in precision oncology and is used today by more than 50% of U.S. oncologists. Last week, SignateraTM CDx became the first FDA-approved companion diagnostic in molecular residual disease testing.
Natera is also continuing to support substantial investments in research and development, with participation in hundreds of clinical trials and research collaborations across its business. These efforts are helping generate the evidence needed to expand the use of personalized diagnostics and bring new innovations to patients worldwide.
“With this expansion, we will have an even greater opportunity to serve patients,” said John Fesko, president, chief business officer of Natera. “By expanding our lab space and sequencing capacity, we are investing in the infrastructure needed to serve more patients, support additional clinicians, and continue advancing personalized medicine at scale.”
Natera expects to create up to 400 new jobs across professional, laboratory, and operational roles through this expansion.
About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
